Intraocular lenses (IOLs) are implantable optical devices for treating cataracts or myopia. IOLs typically replace native crystalline lenses that are cloudy or otherwise discolored due to cataracts. An IOL is surgically implanted by removing the native crystalline lens and then inserting an IOL into the native lens capsule. The World Health Organization estimates that 20 million IOLs were implanted worldwide in 2010 and predicts that 30 million IOLs will be implanted annually by 2020.
Many current IOLs have a single optical power that is set by the manufacturer. As a result, conventional single-power IOLs have a fixed optical power. This requires practitioners to determine the optical power of single-power IOLs before implantation. The optical power of an IOL, however, may not be correct after implantation because the IOL may not fit properly in the native lens capsule or the eye may change over time. If the optical power of an implanted single-power IOL is not correct, the IOL will need to be replaced with another IOL having a suitable optical power via another surgical procedure. This not only increases the cost of healthcare, but it is also inconvenient for the patients and subject to the normal complications of optical surgical procedures.
Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily drawn to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. Furthermore, components can be shown as transparent in certain views for clarity of illustration only and not to indicate that the component is necessarily transparent. Components may also be shown schematically.
Several embodiments of adjustable power intraocular lenses (APIOLs) in accordance with the present technology are described below with reference to
The disclosed APIOLs provide the ability to selectively change the optical power in situ to adapt the APIOLs to the specific power required by the patient after implantation without removing and/or replacing the APIOLs. For example, several embodiments of APIOLs in accordance with the present technology include first volume control elements that release or expel a transport substance and/or second volume control elements that absorb or otherwise attract and retain a transport substance. The first volume control elements can be shrinking elements or release elements configured to release the transport substance upon non-invasive activation, such as an energy modality that selectively reacts with the first volume control elements. Conversely, the second volume control elements can be swelling elements configured to absorb or otherwise attract and retain the transport substance upon non-invasive activation. In operation, the shrinking elements can be activated to release the transport substance from the APIOL to reduce the optical power, or conversely the swelling elements can be activated to absorb the transport substance to increase the optical power.
APIOLs in accordance with present technology can include a container, an optical fluid in the container, and volume control elements in the container. The container can comprise a peripheral component and an optical component. The optical component, for example, can include an anterior optical element and a posterior optical element. The optical elements may be hydrophilic or hydrophobic. The container can comprise a water permeable material. One suitable water permeable material for the container comprises:
The internal optical fluid filling the container can comprise an oil. For example, the oil can have a refractive index greater than that of the aqueous humor. The oil can be capable of holding a saturation volume of water in solution at body temperatures of a human eye. The transport substance can be water.
The volume control elements can include first volume control elements configured to release a transport substance into the optical fluid in the container and/or second volume control elements configured to absorb a transport substance from the optical fluid. The first volume control elements can be shrinking elements that, when activated, release the transport substance into the optical fluid and thereby increase the volume of the transport substance in the fluid chamber. This causes the transport substance concentration within the container to exceed the saturation point such the transport substance is transported out of the container to the aqueous humor by diffusion. The reduction in the transport substance reduces the volume of matter in the container, which in turn reduces the optical power of the optical component. The second volume control elements can be swelling elements that, when activated, absorb the transport substance from the optical fluid. This too causes an imbalance of the transport substance within the container such that additional transport substance is transported from the aqueous humor into the container via diffusion. The increase in the transport substance increases the volume of matter in the container, which in turn increase the optical power of the optical component.
The first volume control elements, or shrinking elements, can include a first hydrophobic casing containing a volume of the transport substance. For example, the transport substance can be water and the first hydrophobic casing can be wax or a liposome (e.g., a uni-laminar liposome). In one example, the first volume control elements can be wax closed-cell foams containing water.
The second volume control elements, or swelling elements, can include one or more hydrophilic elements surrounded by a second hydrophobic casing. The hydrophilic elements can include a hydrogel such as acrylic polymers. The second hydrophobic casing can include parylene and/or a hydrophobic acrylic.
The first and/or second volume control elements can be fixed to the container. In other embodiments, the first and/or second volume control elements can be suspended in the optical fluid.
The optical component of APIOLs in accordance with the present technology can be a fluid lens comprising the optical fluid (e.g., oil) bounded by the anterior optical element and the posterior optical element. The peripheral component can surround the optical component such that the optical component is a central portion of the container. In some embodiments, one or both of the anterior and posterior optical elements may have an optical power (i.e., a defined curvature in a relaxed unbiased state) such that the optical component has an optical power in a relaxed state. In other embodiments, the anterior and/or posterior optical elements may be flat membranes that have no optical power in a relaxed unbiased state such that the optical component has no power in the relaxed state. The total volume of the optical fluid, transport substance and first and/or second volume control elements within the container can change the curvature, and thus the optical power, of the optical component. More specifically, the optical power increases when the volume of matter within the container increases, or conversely the optical power decreases when the volume of matter within the container decreases.
The volume of matter within the container is controlled by selectively activating the first volume control elements or the second volume control elements. The first or second volume control elements can be activated by disrupting all or a portion of the hydrophobic casings of the volume control elements. For example, in several embodiments the volume control elements are activated by exposing the volume control elements to a non-invasive activation energy that selectively disrupts either the first hydrophobic casings of the first volume control elements or the second hydrophobic casings of the second volume control elements. The non-invasive activation energy can include laser energy (e.g., light), ultrasound, electrical energy (e.g., radio frequency), and/or infrared.
The optical component 120 can have an anterior optical element 122 coupled to an anterior portion of the peripheral component 110, a posterior optical element 124 coupled to a posterior portion of the peripheral component 110, and a fluid chamber 126 between the anterior optical element 122 and the posterior optical element 124. The anterior optical element 122 can be a first membrane, and the posterior optical element 124 can be a second membrane. The first and second membranes can have an optical power (e.g., have a set or minimum curvature) or they can have no optical power in a relaxed, unbiased state (e.g., horizontal in
The APIOL 100 can further include first volume control elements 140 and/or second volume control elements 160. The first volume control elements 140 can be shrinking elements or release elements configured to disgorge or otherwise release a transport substance using a first non-invasive activation modality. Conversely, the second volume control elements 160 can be swelling elements configured to absorb or otherwise attract and retain a substance using a second non-invasive activation modality. The first and second non-invasive activation modalities can be one or more types of energy, such as laser radiation, ultrasonic energy, radio frequency (RF) energy or infrared radiation, that selectively activates one or both of the first and second volume control elements 140 and 160. In several embodiments, the first non-invasive activation modality activates only the first volume control elements 140 and the second non-invasive activation modality activates only the second volume control elements 160 such that the first and second volume control elements 140 and 160 can be activated independently of each other. For example, the first volume control elements 140 can be activated by one type of energy (e.g., laser energy), while the second volume control elements 160 can be activated by a different type of energy (e.g., RF energy). In a different example, the first and second volume control elements 140 and 160 can be activated by a common type of energy at different wavelengths or frequencies. In this example the first volume control elements 140 can be activated by a type of energy at a first wavelength or frequency (e.g., laser energy in a first bandwidth) and the second volume control elements 160 can be activated by the same type of energy at a second wavelength or frequency (e.g., laser energy in a second bandwidth). The second bandwidth is sufficiently different than the first bandwidth to avoid joint activation of the first and second volume control elements. In other embodiments, a single non-invasive activation modality can activate both the first volume control elements 140 and the second volume control elements 160. Upon activation, the first and second volume control elements 140 and 160 can become first and second activated elements 142 and 162, respectively.
The optical fluid 128 and the transport substance (not shown in
The first volume control elements 140 can have a thin outer wall and a volume of the transport substance within the thin outer wall. For example, the first volume control elements 140 can have a thin wax shell and a small volume of water encased within the shell. In other embodiments, the first volume control elements 140 can have water encased by a liposome shell, such as a uni-laminar liposome shell having of a bilayer lipid outer membrane. In other embodiments, the first volume control elements 140 can be a closed-cell wax foam with water in the voids of the closed-cell foam.
The second volume control elements 160 can comprise of an outer surface of hydrophobic material encasing either a hydrophilic material or a material which can diffuse or otherwise pass through the optical fluid 128 and/or some portion of the peripheral wall of the APIOL. For example, the second volume control elements 160 described herein can include a small volume of a dehydrated hydrogel encased in a thin layer of wax, a parylene coating, or a layer of an amphiphilic material such that the hydrophilic head groups are presented as the outer surface of the hydrogel and the hydrophobic tail groups are presented outwardly to the environment forming a micelle. The second volume control elements 160 can also be a closed-cell wax foam wherein the voids within the foam contain hydrogel.
The volume control elements 140, 160 described above can be activated by controllably disrupting the shells or outer coating layers thereby allowing a controlled amount of the contained material to access the local environment. Such energy may be one or any combination of laser energy, ultrasound, electrical energy including RF, and infrared energy. In some embodiments, the disruption is accomplished by the delivery of laser energy to the volume control elements. In some embodiments, the first volume control elements 140 and the second volume control elements 160 are activated by different wavelengths of laser energy or different frequencies of ultrasonic or electrical energies. For example, a first wavelength of laser energy is used to activate the first volume control elements 140, while a second different wavelength of laser energy is used to activate the second volume control elements 160. Such selectivity may be built into the volume control elements by controlling the absorbance of the coating material and or the size of the volume control element. In alternative embodiments, the first and second volume control elements 140, 160 may be compartmentalized such that they can be addressed separately as described above with reference to
The accommodating structure 910 can have an accommodating optical element 920 (e.g., an accommodating fluid lens) having a first optical component 921 defining an anterior side of the inner fluid chamber 918 and a second optical component 922 defining a posterior side of the inner fluid chamber 918. The first and second optical components 921 and 922 can be flexible membranes that do not have an optical power, or in other embodiments one or both of the first and second components 921 and 922 can be flexible lenses that have an optical power. In operation, fluid flows between the outer fluid reservoir 914 and the inner chamber 918 in response to the movement of the ciliary muscles of the native eye. For example, when the ciliary muscles relax, the capsular bag pushes against the outer fluid reservoir 914, which in turn causes fluid to flow into the inner chamber 918 and deflect the first optical component 921 anteriorly. This increases the thickness of the accommodating optical element 920. Conversely, when the ciliary muscles contract, the capsular bag is pulled radially outward such that the force exerted against the outer fluid reservoir 914 decreases allowing the higher-pressure fluid in the inner chamber 918 to flow into the outer fluid reservoir 914. This decreases the thickness along the optical axis (e.g., curvature) of the accommodating optical element 920.
The APIOL 900 includes flow-through features 950 that enhance the rate and ease with which Ophthalmic Viscosurgical Devices (OVDs) used during the implantation of AIOLs can be removed from the natural lens capsule. The APIOL 900 can have three outer flow-through features 950. The outer flow-through features 950 can be detents, such as a recess, distributed circumferentially along the perimeter of the outer fluid reservoir 914. In the illustrated embodiment, the flow-through features 950 are formed in regions of the first and second components 911 and 912. Although three outer flow-through features 950 are illustrated, other embodiments may comprise less or more than illustrated. The outer flow-through features 950 may additionally constrain rotation of the APIOL 900 in the eye.
The APIOL 900 additionally comprises a fixed lens assembly 930. The fixed lens assembly 930 illustrated in
Referring to
The fixed lens assembly 930 can be implanted after the accommodating portion 910 has been implanted. This is expected to be advantageous because the accommodating portion 910 can be implanted and then a fixed lens assembly 930 with the desired power can be selected and implanted later based on the actual post-implant optical power of the accommodating portion 910. The fixed lens assembly 930 can also be removed after being attached to the accommodating structure 910. This is advantageous if the fixed lens assembly 930 that was initially implanted is not correct or was damaged while being inserted into the accommodating structure 910.
The APIOL 900 can further include a square-shaped annular region 951 that inhibits cell migration from the periphery of the patient's capsule to the optical part of APIOL 900 (shown in
Referring to
One embodiment of an oil suitable for the optical fluid 128 described above may be compounded by combining volumes of the following materials. Both equilibrium water content and refractive index can be adjusted by varying the proportions of the following components:
This application is a 35 U.S.C. § 371 U.S. National Phase application of International Patent Application No. PCT/US2018/036548, filed Jun. 7, 2018, and entitled ADJUSTABLE OPTICAL POWER INTRAOCULAR LENSES, which claims priority to U.S. Provisional Application No. 62/516,541, filed Jun. 7, 2017, and entitled ADJUSTABLE INTRAOCULAR LENS, the contents of each of the above applications are incorporated herein by reference in their entireties.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2018/036548 | 6/7/2018 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2018/227014 | 12/13/2018 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4440918 | Rice et al. | Apr 1984 | A |
4663409 | Friends et al. | May 1987 | A |
4709996 | Michelson | Dec 1987 | A |
4731078 | Stoy et al. | Mar 1988 | A |
4731080 | Galin | Mar 1988 | A |
4842601 | Smith et al. | Jun 1989 | A |
4892543 | Turley | Jan 1990 | A |
4932966 | McMaster et al. | Jun 1990 | A |
4932971 | Kelman | Jun 1990 | A |
5074942 | Orlosky et al. | Dec 1991 | A |
5211662 | Barrett et al. | May 1993 | A |
5217491 | Vanderbilt | Jun 1993 | A |
5366502 | Patel | Nov 1994 | A |
5405386 | Rheinish et al. | Apr 1995 | A |
5423929 | Grisoni et al. | Jun 1995 | A |
5489302 | Skottun | Feb 1996 | A |
5556929 | Yokoyama et al. | Sep 1996 | A |
5612391 | Chabrecek et al. | Mar 1997 | A |
5620720 | Glick et al. | Apr 1997 | A |
5807944 | Hirt et al. | Sep 1998 | A |
5891931 | Leboeuf et al. | Apr 1999 | A |
5914355 | Kuenzler | Jun 1999 | A |
5944753 | Galin et al. | Aug 1999 | A |
5945465 | Ozark et al. | Aug 1999 | A |
5945498 | Lohmann et al. | Aug 1999 | A |
6140438 | Kawaguchi et al. | Oct 2000 | A |
6346594 | Watanabe et al. | Feb 2002 | B1 |
6447920 | Chabrecek et al. | Sep 2002 | B1 |
6465056 | Chabrecek et al. | Oct 2002 | B1 |
6521352 | Lohmann et al. | Feb 2003 | B1 |
6537316 | Chambers | Mar 2003 | B1 |
6558420 | Green et al. | May 2003 | B2 |
6582754 | Pasic et al. | Jun 2003 | B1 |
6586038 | Chabrecek et al. | Jul 2003 | B1 |
6630243 | Ozark et al. | Oct 2003 | B2 |
6660035 | Yaross et al. | Dec 2003 | B1 |
6685741 | Landreville et al. | Feb 2004 | B2 |
6695881 | Peng et al. | Feb 2004 | B2 |
6713583 | Liao et al. | Mar 2004 | B2 |
6730123 | Klopotek et al. | May 2004 | B1 |
6734321 | Chabrecek et al. | May 2004 | B2 |
6747090 | Haitjema et al. | Jun 2004 | B2 |
6761737 | Ting et al. | Jul 2004 | B2 |
6764511 | Ting et al. | Jul 2004 | B2 |
6767363 | Green et al. | Jul 2004 | B1 |
6767979 | Muir et al. | Jul 2004 | B1 |
6786934 | Ting et al. | Sep 2004 | B2 |
6797004 | Brady et al. | Sep 2004 | B1 |
6818017 | Shu et al. | Nov 2004 | B1 |
6818158 | Pham et al. | Nov 2004 | B2 |
6835410 | Chabrecek et al. | Dec 2004 | B2 |
6846326 | Nguyen et al. | Jan 2005 | B2 |
6858040 | Ting et al. | Feb 2005 | B2 |
6884261 | Zadno-Azizi et al. | Apr 2005 | B2 |
6893595 | Muir et al. | May 2005 | B1 |
6893685 | Pasic et al. | May 2005 | B2 |
6899732 | Zadno-Azizi et al. | May 2005 | B2 |
6935743 | Shadduck | Aug 2005 | B2 |
6969403 | Yang et al. | Nov 2005 | B2 |
7041134 | Ting et al. | May 2006 | B2 |
7087080 | Ting et al. | Aug 2006 | B2 |
7097660 | Portney | Aug 2006 | B2 |
7118596 | Ting et al. | Oct 2006 | B2 |
7198640 | Nguyen | Apr 2007 | B2 |
7217778 | Flipsen et al. | May 2007 | B2 |
7226478 | Ting et al. | Jun 2007 | B2 |
7300464 | Tran | Nov 2007 | B2 |
7416562 | Gross et al. | Aug 2008 | B2 |
7438723 | Esch | Oct 2008 | B2 |
7452378 | Ting et al. | Nov 2008 | B2 |
7468397 | Schorzman et al. | Dec 2008 | B2 |
7479530 | Chan et al. | Jan 2009 | B2 |
7557231 | Schorzman et al. | Jul 2009 | B2 |
7588334 | Matsushita et al. | Sep 2009 | B2 |
7591849 | Richardson et al. | Sep 2009 | B2 |
7601766 | Schorzman et al. | Oct 2009 | B2 |
7637947 | Scholl et al. | Dec 2009 | B2 |
7714090 | Iwamoto et al. | May 2010 | B2 |
7744603 | Zadno-Azizi et al. | Jun 2010 | B2 |
7744646 | Zadno-Azizi et al. | Jun 2010 | B2 |
7781558 | Schorzman et al. | Aug 2010 | B2 |
7806929 | Brown et al. | Oct 2010 | B2 |
7806930 | Brown et al. | Oct 2010 | B2 |
7842087 | Ben | Nov 2010 | B2 |
7883540 | Niwa et al. | Feb 2011 | B2 |
7906563 | Huang et al. | Mar 2011 | B2 |
7942929 | Linhardt et al. | May 2011 | B2 |
8003710 | Medina et al. | Aug 2011 | B2 |
8025823 | Figueroa et al. | Sep 2011 | B2 |
8034107 | Stenger et al. | Oct 2011 | B2 |
8048155 | Shadduck et al. | Nov 2011 | B2 |
8071703 | Zhou et al. | Dec 2011 | B2 |
8105623 | Schorzman et al. | Jan 2012 | B2 |
8158712 | Your | Apr 2012 | B2 |
8187325 | Zadno-Azizi et al. | May 2012 | B2 |
8211955 | Chang et al. | Jul 2012 | B2 |
8222360 | Liao | Jul 2012 | B2 |
8251509 | Zickler et al. | Aug 2012 | B2 |
8283429 | Zhou et al. | Oct 2012 | B2 |
8328869 | Burns et al. | Dec 2012 | B2 |
8357771 | Medina et al. | Jan 2013 | B2 |
8377123 | Zadno et al. | Feb 2013 | B2 |
8414646 | Gifford et al. | Apr 2013 | B2 |
8420711 | Awasthi et al. | Apr 2013 | B2 |
8425595 | Evans et al. | Apr 2013 | B2 |
8425599 | Shadduck et al. | Apr 2013 | B2 |
8425926 | Qiu et al. | Apr 2013 | B2 |
8430928 | Liao | Apr 2013 | B2 |
8454688 | Evans et al. | Jun 2013 | B2 |
8486142 | Bumbalough et al. | Jul 2013 | B2 |
8500806 | Phillips et al. | Aug 2013 | B1 |
8585758 | Woods | Nov 2013 | B2 |
8603166 | Park | Dec 2013 | B2 |
8609745 | Medina et al. | Dec 2013 | B2 |
8663510 | Graney et al. | Mar 2014 | B2 |
8680172 | Liao | Mar 2014 | B2 |
8728158 | Whitsett | May 2014 | B2 |
8759414 | Winter et al. | Jun 2014 | B2 |
8784485 | Evans et al. | Jul 2014 | B2 |
8827447 | Awasthi et al. | Sep 2014 | B2 |
8834566 | Jones | Sep 2014 | B1 |
8835525 | Chang et al. | Sep 2014 | B2 |
8851670 | Zickler et al. | Oct 2014 | B2 |
8863749 | Gooding et al. | Oct 2014 | B2 |
8877227 | Ravi | Nov 2014 | B2 |
8899745 | Domschke | Dec 2014 | B2 |
8900298 | Chazan et al. | Dec 2014 | B2 |
8956409 | Ben | Feb 2015 | B2 |
8968399 | Ghabra | Mar 2015 | B2 |
8992609 | Shadduck | Mar 2015 | B2 |
8993651 | Chang et al. | Mar 2015 | B2 |
9005492 | Chang et al. | Apr 2015 | B2 |
9005700 | Qiu et al. | Apr 2015 | B2 |
9006359 | Schultz et al. | Apr 2015 | B2 |
9011532 | Catlin et al. | Apr 2015 | B2 |
9023915 | Hu et al. | May 2015 | B2 |
9034035 | Assia et al. | May 2015 | B2 |
9039174 | Awasthi et al. | May 2015 | B2 |
9044302 | Gooding et al. | Jun 2015 | B2 |
9052439 | Samuel et al. | Jun 2015 | B2 |
9052440 | Chang et al. | Jun 2015 | B2 |
9095424 | Atkinson et al. | Aug 2015 | B2 |
9097840 | Chang et al. | Aug 2015 | B2 |
9125736 | Atkinson et al. | Sep 2015 | B2 |
9186244 | Rao et al. | Nov 2015 | B2 |
9198572 | Zickler et al. | Dec 2015 | B2 |
9198752 | Woods | Dec 2015 | B2 |
9254189 | Azar et al. | Feb 2016 | B2 |
9265604 | Woods | Feb 2016 | B2 |
9280000 | Simonov et al. | Mar 2016 | B2 |
9289287 | Atkinson et al. | Mar 2016 | B2 |
9326848 | Woods | May 2016 | B2 |
9364316 | Kahook et al. | Jun 2016 | B1 |
9387069 | Atkinson et al. | Jul 2016 | B2 |
9398949 | Werblin | Jul 2016 | B2 |
9421088 | Schieber et al. | Aug 2016 | B1 |
9427312 | Tai et al. | Aug 2016 | B2 |
9456895 | Shadduck et al. | Oct 2016 | B2 |
9486311 | Vaughan et al. | Nov 2016 | B2 |
9498326 | Tsai et al. | Nov 2016 | B2 |
9603703 | Bumbalough | Mar 2017 | B2 |
9622855 | Portney et al. | Apr 2017 | B2 |
9636213 | Brady | May 2017 | B2 |
9655775 | Boukhny et al. | May 2017 | B2 |
9681946 | Kahook et al. | Jun 2017 | B2 |
9693858 | Hildebrand et al. | Jul 2017 | B2 |
9744027 | Jansen | Aug 2017 | B2 |
9795473 | Smiley et al. | Oct 2017 | B2 |
9814568 | Ben Nun | Nov 2017 | B2 |
9907881 | Terrisse | Mar 2018 | B2 |
10195018 | Salahieh et al. | Feb 2019 | B2 |
10350057 | Argento et al. | Jul 2019 | B2 |
10526353 | Silvestrini | Jan 2020 | B2 |
10548718 | Salahieh et al. | Feb 2020 | B2 |
10709549 | Argento et al. | Jul 2020 | B2 |
10736734 | Salahieh et al. | Aug 2020 | B2 |
11065109 | Argento et al. | Jul 2021 | B2 |
20010037001 | Muller et al. | Nov 2001 | A1 |
20010056165 | Mentak et al. | Dec 2001 | A1 |
20020072795 | Green et al. | Jun 2002 | A1 |
20020086160 | Qiu et al. | Jul 2002 | A1 |
20020102415 | Valint, Jr. et al. | Aug 2002 | A1 |
20020103536 | Landreville et al. | Aug 2002 | A1 |
20020107568 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020111678 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020116057 | Ting et al. | Aug 2002 | A1 |
20020116058 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020116059 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020116060 | Nguyen et al. | Aug 2002 | A1 |
20020116061 | Zadno-Azizi et al. | Aug 2002 | A1 |
20020138141 | Zadno-Azizi et al. | Sep 2002 | A1 |
20020173847 | Pham et al. | Nov 2002 | A1 |
20020197414 | Chabrecek et al. | Dec 2002 | A1 |
20030008063 | Chabrecek et al. | Jan 2003 | A1 |
20030074060 | Zadno-Azizi et al. | Apr 2003 | A1 |
20030074061 | Pham et al. | Apr 2003 | A1 |
20030078656 | Nguyen | Apr 2003 | A1 |
20030078657 | Zadno-Azizi et al. | Apr 2003 | A1 |
20030078658 | Zadno-Azizi | Apr 2003 | A1 |
20030100666 | DeGroot et al. | May 2003 | A1 |
20030158560 | Portney | Aug 2003 | A1 |
20030162929 | Verbruggen et al. | Aug 2003 | A1 |
20030224185 | Valint, Jr. et al. | Dec 2003 | A1 |
20040082993 | Woods | Apr 2004 | A1 |
20040111152 | Kelman et al. | Jun 2004 | A1 |
20040166232 | Kunzler et al. | Aug 2004 | A1 |
20040169816 | Esch | Sep 2004 | A1 |
20040184158 | Shadduck | Sep 2004 | A1 |
20040230300 | Bandhauer et al. | Nov 2004 | A1 |
20050013842 | Qiu et al. | Jan 2005 | A1 |
20050049700 | Zadno-Azizi et al. | Mar 2005 | A1 |
20050055092 | Nguyen et al. | Mar 2005 | A1 |
20050149183 | Shadduck et al. | Jul 2005 | A1 |
20050153055 | Ammon et al. | Jul 2005 | A1 |
20050165410 | Zadno-Azizi et al. | Jul 2005 | A1 |
20050228120 | Hughes et al. | Oct 2005 | A1 |
20050228401 | Zadno-Azizi et al. | Oct 2005 | A1 |
20060069432 | Tran | Mar 2006 | A1 |
20060100701 | Esch et al. | May 2006 | A1 |
20060100703 | Evans et al. | May 2006 | A1 |
20060116765 | Blake et al. | Jun 2006 | A1 |
20060178741 | Zadno-Azizi et al. | Aug 2006 | A1 |
20060241752 | Israel | Oct 2006 | A1 |
20060259139 | Zadno-Azizi et al. | Nov 2006 | A1 |
20060271187 | Zadno-Azizi et al. | Nov 2006 | A1 |
20070027540 | Zadno-Azizi et al. | Feb 2007 | A1 |
20070050025 | Nguyen et al. | Mar 2007 | A1 |
20070078515 | Brady | Apr 2007 | A1 |
20070088433 | Esch | Apr 2007 | A1 |
20070092830 | Lai et al. | Apr 2007 | A1 |
20070106377 | Smith et al. | May 2007 | A1 |
20070108643 | Zadno-Azizi et al. | May 2007 | A1 |
20070122540 | Salamone et al. | May 2007 | A1 |
20070201138 | Lo et al. | Aug 2007 | A1 |
20070203317 | Verbruggen et al. | Aug 2007 | A1 |
20070213817 | Esch et al. | Sep 2007 | A1 |
20070232755 | Matsushita et al. | Oct 2007 | A1 |
20070269488 | Ravi et al. | Nov 2007 | A1 |
20080001318 | Schorzman et al. | Jan 2008 | A1 |
20080003259 | Salamone et al. | Jan 2008 | A1 |
20080003261 | Schorzman et al. | Jan 2008 | A1 |
20080015689 | Esch et al. | Jan 2008 | A1 |
20080027461 | Vaquero et al. | Jan 2008 | A1 |
20080046074 | Smith et al. | Feb 2008 | A1 |
20080076897 | Kunzler et al. | Mar 2008 | A1 |
20080139769 | Iwamoto et al. | Jun 2008 | A1 |
20080143958 | Medina et al. | Jun 2008 | A1 |
20080181931 | Qiu et al. | Jul 2008 | A1 |
20080234457 | Zhou et al. | Sep 2008 | A1 |
20080300680 | Joshua et al. | Dec 2008 | A1 |
20080314767 | Lai et al. | Dec 2008 | A1 |
20090043384 | Niwa et al. | Feb 2009 | A1 |
20090076603 | Avery et al. | Mar 2009 | A1 |
20090118739 | Kappelhof et al. | May 2009 | A1 |
20090143499 | Chang et al. | Jun 2009 | A1 |
20090168012 | Linhardt et al. | Jul 2009 | A1 |
20090170976 | Huang et al. | Jul 2009 | A1 |
20090171459 | Linhardt et al. | Jul 2009 | A1 |
20090204210 | Pynson | Aug 2009 | A1 |
20090232871 | Hitz et al. | Sep 2009 | A1 |
20090247661 | Muller-Lierheim et al. | Oct 2009 | A1 |
20090292355 | Boyd et al. | Nov 2009 | A1 |
20100016964 | Werblin | Jan 2010 | A1 |
20100119744 | Yokoyama et al. | May 2010 | A1 |
20100120938 | Phelan et al. | May 2010 | A1 |
20100120939 | Phelan et al. | May 2010 | A1 |
20100121444 | Ben et al. | May 2010 | A1 |
20100160482 | Nachbaur et al. | Jun 2010 | A1 |
20100179653 | Argento et al. | Jul 2010 | A1 |
20100211170 | Liao et al. | Aug 2010 | A1 |
20100228346 | Esch et al. | Sep 2010 | A1 |
20100239633 | Strome et al. | Sep 2010 | A1 |
20100324674 | Brown et al. | Dec 2010 | A1 |
20110009519 | Awasthi et al. | Jan 2011 | A1 |
20110046332 | Breiner et al. | Feb 2011 | A1 |
20110112636 | Ben Nun | May 2011 | A1 |
20110118379 | Tighe et al. | May 2011 | A1 |
20110118834 | Lo et al. | May 2011 | A1 |
20110133350 | Qiu et al. | Jun 2011 | A1 |
20110140292 | Chang et al. | Jun 2011 | A1 |
20110144228 | Ravi et al. | Jun 2011 | A1 |
20110269869 | Medina et al. | Nov 2011 | A1 |
20110282442 | Scholl et al. | Nov 2011 | A1 |
20110295368 | Betser | Dec 2011 | A1 |
20120010321 | Chang et al. | Jan 2012 | A1 |
20120023869 | Samuel et al. | Feb 2012 | A1 |
20120033183 | Dai et al. | Feb 2012 | A1 |
20120041097 | Zhou et al. | Feb 2012 | A1 |
20120046743 | Pinchuk et al. | Feb 2012 | A1 |
20120063000 | Batchko et al. | Mar 2012 | A1 |
20120078363 | Lu | Mar 2012 | A1 |
20120078364 | Stenger | Mar 2012 | A1 |
20120088843 | Chang et al. | Apr 2012 | A1 |
20120088844 | Kuyu et al. | Apr 2012 | A1 |
20120088861 | Huang et al. | Apr 2012 | A1 |
20120115979 | Chang et al. | May 2012 | A1 |
20120147323 | Domschke et al. | Jun 2012 | A1 |
20120238857 | Wong et al. | Sep 2012 | A1 |
20120245684 | Liao et al. | Sep 2012 | A1 |
20120314183 | Nakamura et al. | Dec 2012 | A1 |
20120330415 | Callahan et al. | Dec 2012 | A1 |
20130013060 | Zadno-Azizi et al. | Jan 2013 | A1 |
20130053954 | Rao et al. | Feb 2013 | A1 |
20130095235 | Bothe et al. | Apr 2013 | A1 |
20130106007 | Medina et al. | May 2013 | A1 |
20130110234 | DeVita et al. | May 2013 | A1 |
20130116781 | Ben Nun et al. | May 2013 | A1 |
20130150961 | Evans et al. | Jun 2013 | A1 |
20130176628 | Batchko et al. | Jul 2013 | A1 |
20130197125 | Awasthi et al. | Aug 2013 | A1 |
20130224309 | Qiu et al. | Aug 2013 | A1 |
20130228943 | Qiu et al. | Sep 2013 | A1 |
20130245756 | Liao et al. | Sep 2013 | A1 |
20130289294 | Awasthi et al. | Oct 2013 | A1 |
20130304203 | Beer | Nov 2013 | A1 |
20130317607 | DeBoer et al. | Nov 2013 | A1 |
20140055750 | Dai et al. | Feb 2014 | A1 |
20140171539 | Chang et al. | Jun 2014 | A1 |
20140171542 | Chang | Jun 2014 | A1 |
20140178595 | Bothe et al. | Jun 2014 | A1 |
20140180403 | Silvestrini et al. | Jun 2014 | A1 |
20140180406 | Simpson | Jun 2014 | A1 |
20140180407 | Sohn et al. | Jun 2014 | A1 |
20140228949 | Argento et al. | Aug 2014 | A1 |
20140277439 | Hu et al. | Sep 2014 | A1 |
20140309735 | Sohn et al. | Oct 2014 | A1 |
20140316521 | McLeod et al. | Oct 2014 | A1 |
20140350124 | Chang et al. | Nov 2014 | A1 |
20140379079 | Ben Nun | Dec 2014 | A1 |
20150088149 | Auld | Mar 2015 | A1 |
20150092155 | Chang et al. | Apr 2015 | A1 |
20150105760 | Silvestrini et al. | Apr 2015 | A1 |
20150152228 | Chang et al. | Jun 2015 | A1 |
20150164321 | Weibel et al. | Jun 2015 | A1 |
20150173892 | Borja et al. | Jun 2015 | A1 |
20150177417 | Goshima et al. | Jun 2015 | A1 |
20150351901 | Chicevic et al. | Dec 2015 | A1 |
20160000558 | Honigsbaum et al. | Jan 2016 | A1 |
20160008126 | Vaughan et al. | Jan 2016 | A1 |
20160030161 | Rao et al. | Feb 2016 | A1 |
20160058553 | Vaughan et al. | Mar 2016 | A1 |
20160074154 | Woods | Mar 2016 | A1 |
20160100938 | Weeber et al. | Apr 2016 | A1 |
20160128826 | Rao et al. | May 2016 | A1 |
20160151150 | Sato | Jun 2016 | A1 |
20160184091 | Burns et al. | Jun 2016 | A1 |
20160184092 | Flaherty et al. | Jun 2016 | A1 |
20160250020 | Schieber et al. | Sep 2016 | A1 |
20160256265 | Borja et al. | Sep 2016 | A1 |
20160262875 | Smiley et al. | Sep 2016 | A1 |
20160278914 | Sato et al. | Sep 2016 | A1 |
20160296320 | Humayun et al. | Oct 2016 | A1 |
20160296662 | Dudic et al. | Oct 2016 | A1 |
20160317286 | Rao et al. | Nov 2016 | A1 |
20160317287 | Rao et al. | Nov 2016 | A1 |
20160331587 | Ueno et al. | Nov 2016 | A1 |
20160361157 | Honigsbaum | Dec 2016 | A1 |
20170000602 | Sohn et al. | Jan 2017 | A1 |
20170020662 | Shadduck | Jan 2017 | A1 |
20170049561 | Smiley et al. | Feb 2017 | A1 |
20170049562 | Argento et al. | Feb 2017 | A1 |
20170119521 | Kahook et al. | May 2017 | A1 |
20170258581 | Borja et al. | Sep 2017 | A1 |
20170348094 | Sohn et al. | Dec 2017 | A1 |
20180110613 | Wortz et al. | Apr 2018 | A1 |
20180161152 | Argento et al. | Jun 2018 | A1 |
20180177589 | Argento et al. | Jun 2018 | A1 |
20190159890 | Salahieh et al. | May 2019 | A1 |
20190274823 | Argento et al. | Sep 2019 | A1 |
20190290422 | Ben Nun | Sep 2019 | A1 |
20190374334 | Brady et al. | Dec 2019 | A1 |
20200121447 | Argento et al. | Apr 2020 | A1 |
20200306031 | Salahieh et al. | Oct 2020 | A1 |
20200397566 | Salahieh et al. | Dec 2020 | A1 |
Number | Date | Country |
---|---|---|
2006200142 | Jul 2006 | AU |
2015361227 | Apr 2017 | AU |
2010203427 | May 2017 | AU |
2012335677 | Jun 2017 | AU |
2015258287 | Dec 2017 | AU |
2973684 | Jul 2016 | CA |
2974639 | Aug 2016 | CA |
2987311 | Dec 2016 | CA |
2752046 | Apr 2017 | CA |
2829143 | Apr 2017 | CA |
1285722 | Feb 2001 | CN |
1795090 | Jun 2006 | CN |
101351169 | Jun 2007 | CN |
101031257 | Sep 2007 | CN |
101641060 | Nov 2007 | CN |
101277659 | Oct 2008 | CN |
101360468 | Feb 2009 | CN |
101069106 | Feb 2010 | CN |
102271623 | Jul 2010 | CN |
108472129 | Aug 2018 | CN |
101547663 | Jan 2021 | CN |
0604369 | Jun 1994 | EP |
0734269 | Oct 1996 | EP |
0784652 | Jul 1997 | EP |
0800511 | Oct 1997 | EP |
0820601 | Jan 1998 | EP |
0826158 | Mar 1998 | EP |
0898972 | Mar 1999 | EP |
0907668 | Apr 1999 | EP |
0930357 | Jul 1999 | EP |
0604369 | Aug 1999 | EP |
0826158 | Sep 1999 | EP |
0947856 | Oct 1999 | EP |
0820601 | Dec 1999 | EP |
0800511 | Jan 2000 | EP |
0989138 | Mar 2000 | EP |
1084428 | Mar 2001 | EP |
1088246 | Apr 2001 | EP |
1090313 | Apr 2001 | EP |
1095711 | May 2001 | EP |
1095965 | May 2001 | EP |
1095966 | May 2001 | EP |
1109853 | Jun 2001 | EP |
0907668 | Sep 2001 | EP |
1141054 | Oct 2001 | EP |
1187873 | Mar 2002 | EP |
1200019 | May 2002 | EP |
1227773 | Aug 2002 | EP |
1230041 | Aug 2002 | EP |
1266246 | Dec 2002 | EP |
0898972 | Apr 2003 | EP |
1341485 | Sep 2003 | EP |
1364663 | Nov 2003 | EP |
1095711 | Jan 2004 | EP |
1141054 | Feb 2004 | EP |
1395302 | Mar 2004 | EP |
1410074 | Apr 2004 | EP |
1266246 | Jun 2004 | EP |
1109853 | Sep 2004 | EP |
1187873 | Sep 2004 | EP |
1084428 | Nov 2004 | EP |
1472305 | Nov 2004 | EP |
1230041 | Dec 2004 | EP |
0989138 | Feb 2005 | EP |
1095965 | Feb 2005 | EP |
1395302 | Feb 2005 | EP |
1507811 | Feb 2005 | EP |
1524953 | Apr 2005 | EP |
1200019 | Sep 2005 | EP |
1095966 | Jan 2006 | EP |
1660153 | May 2006 | EP |
1353611 | Sep 2006 | EP |
1696975 | Sep 2006 | EP |
1341485 | Nov 2006 | EP |
1723933 | Nov 2006 | EP |
1723934 | Nov 2006 | EP |
1750157 | Feb 2007 | EP |
1088246 | Nov 2007 | EP |
1857477 | Nov 2007 | EP |
1227773 | Jan 2008 | EP |
1888660 | Feb 2008 | EP |
1890650 | Feb 2008 | EP |
1902737 | Mar 2008 | EP |
1723933 | Nov 2008 | EP |
2035050 | Mar 2009 | EP |
2035480 | Mar 2009 | EP |
2035486 | Mar 2009 | EP |
1723934 | Jun 2009 | EP |
2066732 | Jun 2009 | EP |
2077292 | Jul 2009 | EP |
2092376 | Aug 2009 | EP |
1648534 | Sep 2009 | EP |
2094193 | Sep 2009 | EP |
2109784 | Oct 2009 | EP |
2120789 | Nov 2009 | EP |
2126614 | Dec 2009 | EP |
2035480 | Feb 2010 | EP |
2170708 | Apr 2010 | EP |
2185589 | May 2010 | EP |
2231207 | Sep 2010 | EP |
1750157 | Oct 2010 | EP |
2235094 | Oct 2010 | EP |
2276513 | Jan 2011 | EP |
2292672 | Mar 2011 | EP |
2356170 | Aug 2011 | EP |
2356497 | Aug 2011 | EP |
2109784 | Oct 2011 | EP |
2396355 | Dec 2011 | EP |
2035486 | Apr 2012 | EP |
2452212 | May 2012 | EP |
1857477 | Jun 2012 | EP |
1410074 | Oct 2012 | EP |
2092376 | Oct 2012 | EP |
2510051 | Oct 2012 | EP |
2513711 | Oct 2012 | EP |
2514791 | Oct 2012 | EP |
2356170 | Dec 2012 | EP |
2538266 | Dec 2012 | EP |
2563275 | Mar 2013 | EP |
2597113 | May 2013 | EP |
2598936 | Jun 2013 | EP |
2077292 | Aug 2013 | EP |
2625216 | Aug 2013 | EP |
2625217 | Aug 2013 | EP |
2625218 | Aug 2013 | EP |
2652532 | Oct 2013 | EP |
1830898 | Mar 2014 | EP |
2766750 | Aug 2014 | EP |
2452212 | Mar 2015 | EP |
2934383 | Oct 2015 | EP |
2200536 | Jan 2016 | EP |
2976042 | Jan 2016 | EP |
3185818 | Mar 2016 | EP |
2129331 | Apr 2016 | EP |
3003217 | Apr 2016 | EP |
3025678 | Jun 2016 | EP |
2259750 | Jul 2016 | EP |
2934383 | Jul 2016 | EP |
3062741 | Sep 2016 | EP |
3072476 | Sep 2016 | EP |
1999188 | Nov 2016 | EP |
2685935 | Nov 2016 | EP |
2094193 | Jan 2017 | EP |
2683287 | Feb 2017 | EP |
3062742 | Feb 2017 | EP |
3157466 | Apr 2017 | EP |
3160404 | May 2017 | EP |
3160683 | May 2017 | EP |
3049023 | Jun 2017 | EP |
3160683 | Jun 2017 | EP |
3174500 | Jun 2017 | EP |
2539351 | Jul 2017 | EP |
2283058 | Oct 2007 | ES |
2653325 | Apr 1991 | FR |
59-501897 | Nov 1984 | JP |
01-223970 | Sep 1989 | JP |
2006-518222 | Aug 2006 | JP |
2007-506516 | Mar 2007 | JP |
2007-517616 | Jul 2007 | JP |
2010-517639 | May 2010 | JP |
2012-532685 | Dec 2012 | JP |
2016-534816 | Nov 2016 | JP |
9007545 | Jul 1990 | WO |
9007575 | Jul 1990 | WO |
9516475 | Jun 1995 | WO |
9611235 | Apr 1996 | WO |
9620919 | Jul 1996 | WO |
9631791 | Oct 1996 | WO |
9636890 | Nov 1996 | WO |
9749740 | Dec 1997 | WO |
9917684 | Apr 1999 | WO |
9929818 | Jun 1999 | WO |
9957581 | Nov 1999 | WO |
9960428 | Nov 1999 | WO |
9963366 | Dec 1999 | WO |
2000004078 | Jan 2000 | WO |
2000026980 | Jun 2000 | WO |
2000071613 | Nov 2000 | WO |
2001008607 | Feb 2001 | WO |
2001030512 | May 2001 | WO |
2001034067 | May 2001 | WO |
2001071392 | Sep 2001 | WO |
2002047583 | Jun 2002 | WO |
2002094331 | Nov 2002 | WO |
2003009014 | Jan 2003 | WO |
2003066707 | Aug 2003 | WO |
2003097711 | Nov 2003 | WO |
2004010905 | Feb 2004 | WO |
2004046768 | Jun 2004 | WO |
2004052242 | Jun 2004 | WO |
2004053536 | Jun 2004 | WO |
2004054471 | Jul 2004 | WO |
2004058318 | Jul 2004 | WO |
2004072689 | Aug 2004 | WO |
2005023331 | Mar 2005 | WO |
2005065734 | Jul 2005 | WO |
2006047383 | May 2006 | WO |
2006103674 | Oct 2006 | WO |
2006126095 | Nov 2006 | WO |
2007005778 | Jan 2007 | WO |
2007047529 | Apr 2007 | WO |
2007047530 | Apr 2007 | WO |
2007050394 | May 2007 | WO |
2007064594 | Jun 2007 | WO |
2008005644 | Jan 2008 | WO |
2008005652 | Jan 2008 | WO |
2008005752 | Jan 2008 | WO |
2008024766 | Feb 2008 | WO |
2008039655 | Apr 2008 | WO |
2008076729 | Jun 2008 | WO |
2008077040 | Jun 2008 | WO |
2008082957 | Jul 2008 | WO |
2008094876 | Aug 2008 | WO |
2008103798 | Aug 2008 | WO |
2008107882 | Sep 2008 | WO |
2008116132 | Sep 2008 | WO |
2008151088 | Dec 2008 | WO |
2009002703 | Dec 2008 | WO |
2020219456 | Dec 2008 | WO |
2009015161 | Jan 2009 | WO |
2009015226 | Jan 2009 | WO |
2009015234 | Jan 2009 | WO |
2009015240 | Jan 2009 | WO |
2009085755 | Jul 2009 | WO |
2009085756 | Jul 2009 | WO |
2009127844 | Oct 2009 | WO |
2010056686 | May 2010 | WO |
2010056687 | May 2010 | WO |
2010081093 | Jul 2010 | WO |
2010093823 | Aug 2010 | WO |
2011005937 | Jan 2011 | WO |
2011026068 | Mar 2011 | WO |
2011071790 | Jun 2011 | WO |
2011075377 | Jun 2011 | WO |
2011106435 | Sep 2011 | WO |
2012006616 | Jan 2012 | WO |
2012015639 | Feb 2012 | WO |
2012047961 | Apr 2012 | WO |
2012047964 | Apr 2012 | WO |
2012047969 | Apr 2012 | WO |
2012082704 | Jun 2012 | WO |
2012129407 | Sep 2012 | WO |
2021007535 | Sep 2012 | WO |
2012129419 | Apr 2013 | WO |
2013055746 | Apr 2013 | WO |
2013070924 | May 2013 | WO |
2013158942 | Oct 2013 | WO |
2013166068 | Nov 2013 | WO |
2014093751 | Jun 2014 | WO |
2014093764 | Jun 2014 | WO |
2014095690 | Jun 2014 | WO |
2014099630 | Jun 2014 | WO |
2014143926 | Sep 2014 | WO |
2014149462 | Sep 2014 | WO |
2014152017 | Sep 2014 | WO |
2015038620 | Mar 2015 | WO |
2015048279 | Apr 2015 | WO |
2015066502 | May 2015 | WO |
WO2015066532 | May 2015 | WO |
2015148673 | Oct 2015 | WO |
2016018932 | Feb 2016 | WO |
2016018932 | Feb 2016 | WO |
2016033217 | Mar 2016 | WO |
2016038470 | Mar 2016 | WO |
2016061233 | Apr 2016 | WO |
2016122805 | Aug 2016 | WO |
2016133558 | Aug 2016 | WO |
2016140708 | Sep 2016 | WO |
2016195095 | Dec 2016 | WO |
2016201351 | Dec 2016 | WO |
2013059195 | May 2017 | WO |
2017079449 | May 2017 | WO |
2017079733 | May 2017 | WO |
2017087358 | May 2017 | WO |
2009002789 | Dec 2017 | WO |
2017208230 | Dec 2017 | WO |
2017223544 | Dec 2017 | WO |
2018119408 | Jun 2018 | WO |
2017221196 | Aug 2018 | WO |
2018222579 | Dec 2018 | WO |
2018227014 | Dec 2018 | WO |
Entry |
---|
Klank, et al. “CO2-laser micromachining and back-end processing for rapid production of PMMA-based microfluidic systems,” Lab Chip, 2002, 2, 242-246. |
Tsao, et al. “Bonding of thermoplastic polymer microfluidics. Microfluid Nanofuild,” 2009, 6:1-16. |
Umbrecht, et al. “Solvent assisted bonding of polymethylmethacrylate: characterization using the response surface methodology,” 2008, pp. 1325-1328. |
Liang et al., “Bionic intraocular lens with variable focus and integrated structure,” Optical Engineering 2015, vol. 54, No. 10, Article No. 105106, Internal pp. 1-7. |
International Search Report and Written Opinion for PCT Application No. PCT/US2018/036548, filed Jun. 7, 2018, Applicant: Shifamed Holdings, LLC, dated Aug. 30, 2018, 8 pages. |
First Chinese Office Action dated Sep. 10, 2020 for Chinese Patent Application No. 201780087361.6, Applicant: Shifamed Holdings, LLC, filing date: Dec. 23, 2017, 11 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2020/029131, filed Apr. 21, 2020, Applicant: Shifamed Holdings, LLC, dated Sep. 21, 2020, 15 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2020/041644, filed Jul. 10, 2020, Applicant: Shifamed Holdings, LLC, dated Oct. 27, 2020, 11 pages. |
European Extended Search Report dated Jan. 27, 2021 for European Patent Application No. 18809676.2, Applicant: Shifamed Holdings, LLC, filing date: May 29, 2018, 8 pages. |
Chinese Office Action dated Jun. 3, 2021 for Chinese Patent Application No. 201880050631.0, Applicant: Shifamed Holdings, LLC, 7 pages. |
Chinese Office Action dated Feb. 7, 2021 for Chinese Patent Application No. 201680079359.X, Applicant: Shifamed Holdings, LLC, 8 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2021/016760, filed Feb. 5, 2021, Applicant: Shifamed Holdings, LLC, dated Jun. 9, 2021, 14 pages. |
Chinese Office Action dated Aug. 20, 2021 for Chinese Patent Application No. 201910547059.5, Applicant: Shifamed Holdings, LLC, 10 pages. |
Number | Date | Country | |
---|---|---|---|
20200146813 A1 | May 2020 | US |
Number | Date | Country | |
---|---|---|---|
62516541 | Jun 2017 | US |